Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 85% confidence The document is an “Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)” to the Indian stock exchanges enclosing a press release about clinical trial data. It does not contain financial results or an investor presentation, nor is it the text of an earnings release or formal financial report. It is a general regulatory announcement/press release to exchanges, which falls under the Regulatory Filings category.
2026-05-26 English
Press Release
Regulatory Filings Classification · 85% confidence The document is a press release served as an intimation under SEBI Regulation 30 to the Indian stock exchanges, announcing clinical trial data presentation at ASCO. It contains no financial statements or management discussion of quarterly results, nor is it an investor presentation deck. It is a general regulatory announcement to satisfy listing obligations, fitting the “Regulatory Filings (RNS)” fallback category for miscellaneous compliance disclosures.
2026-05-26 English
Intimation of Schedule of Analyst/Institutional Investor Meeting
Regulatory Filings Classification · 85% confidence The document is a formal Stock Exchange disclosure under SEBI LODR Regulation 30, notifying the schedule of upcoming analyst/investor meetings. It contains no financial data or report attachments, nor is it a presentation or transcript. It is a general regulatory announcement, best classified under Regulatory Filings (RNS).
2026-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying stock exchanges of the schedule for analyst/institutional investor meetings. It is a compliance disclosure to regulators/exchanges and does not contain financial results, presentations, or detailed reports. It fits the ‘Regulatory Filings’ category as a general regulatory announcement that does not match other specific filing types.
2026-05-25 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 87% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying stock exchanges that newspaper advertisements containing the Audited Financial Results for the quarter and year ended 31 March 2026 have been published, with copies of clippings attached. There is no substantive financial data included; it merely announces publication and availability of the results on the company’s website and stock exchange websites. This satisfies the ‘Report Publication Announcement’ category, as it is an announcement of the publication of a report rather than the report itself.
2026-05-23 English
Newspaper publication for financial results for the year ended 31 March 2026
Report Publication Announcement Classification · 82% confidence The document is a Reg. 30 SEBI (Listing Obligations & Disclosure Requirements) filing by Sun Pharma (and similarly by TVS Electronics) notifying the publication of “newspaper advertisements containing information about the Audited Financial Results for the quarter and year ended 31 March 2026.” It does not contain the actual financial statements or substantive financial data itself (beyond excerpts in an ad), but rather is an announcement that the audited results have been published and are available on the company’s and stock exchange websites. Under the “MENU VS MEAL” rule, this is not the report itself but an announcement of its publication. Therefore, it best fits the “Report Publication Announcement” category (Code: RPA).
2026-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.